File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pentaglobin in steroid-resistant severe acute respiratory syndrome

TitlePentaglobin in steroid-resistant severe acute respiratory syndrome
Authors
KeywordsCorticosteroid
Immunoglobulin
Pentaglobin
Severe acute respiratory syndrome
Treatment
Issue Date2004
PublisherInternational Union against Tuberculosis and Lung Disease. The Journal's web site is located at http://www.theunion.org/about-the-journal/about-the-journal.html
Citation
International Journal Of Tuberculosis And Lung Disease, 2004, v. 8 n. 10, p. 1173-1179 How to Cite?
AbstractSETTING: The treatment of severe acute respiratory syndrome (SARS) is at best controversial, although there is considerable anecdotal experience to show the benefits of corticosteroid therapy for selected patients. Some patients deteriorate relentlessly despite treatment with antibiotic, corticosteroid and mechanical ventilation. OBJECTIVE: To attempt to determine the clinical efficacy of pentaglobin, an IgM-enriched immunoglobulin preparation, on 12 severe SARS patients who continued to deteriorate despite corticosteroid and ribavirin therapy. DESIGN: Retrospective analysis of daily quantitative and radiographic data on the cohort in a regional teaching hospital. RESULTS AND CONCLUSION: There was significant improvement in radiographic scores, when compared with day 1, on days 5, 6 and 7 (P < 0.05) after commencement of pentaglobin treatment. Similarly, there was significant improvement in oxygen requirement, when compared with day 1, on days 6 and 7 (P < 0.05) after commencement of pentaglobin treatment. There were no reported adverse events attributable to pentaglobin administration. Ten patients made an uneventful recovery after treatment. One elderly man died from cardio-respiratory arrest despite clinical and radiological improvement, and another patient is making good progress. Pentaglobin is safe and probably effective in the treatment of steroid-resistant SARS. A double-blind placebo-controlled study should therefore be considered.
Persistent Identifierhttp://hdl.handle.net/10722/72406
ISSN
2015 Impact Factor: 2.148
2015 SCImago Journal Rankings: 1.381
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHo, JCen_HK
dc.contributor.authorWu, AYen_HK
dc.contributor.authorLam, Ben_HK
dc.contributor.authorOoi, GCen_HK
dc.contributor.authorKhong, PLen_HK
dc.contributor.authorHo, PLen_HK
dc.contributor.authorChanYeung, Men_HK
dc.contributor.authorZhong, NSen_HK
dc.contributor.authorKo, Cen_HK
dc.contributor.authorLam, WKen_HK
dc.contributor.authorTsang, KWen_HK
dc.date.accessioned2010-09-06T06:41:24Z-
dc.date.available2010-09-06T06:41:24Z-
dc.date.issued2004en_HK
dc.identifier.citationInternational Journal Of Tuberculosis And Lung Disease, 2004, v. 8 n. 10, p. 1173-1179en_HK
dc.identifier.issn1027-3719en_HK
dc.identifier.urihttp://hdl.handle.net/10722/72406-
dc.description.abstractSETTING: The treatment of severe acute respiratory syndrome (SARS) is at best controversial, although there is considerable anecdotal experience to show the benefits of corticosteroid therapy for selected patients. Some patients deteriorate relentlessly despite treatment with antibiotic, corticosteroid and mechanical ventilation. OBJECTIVE: To attempt to determine the clinical efficacy of pentaglobin, an IgM-enriched immunoglobulin preparation, on 12 severe SARS patients who continued to deteriorate despite corticosteroid and ribavirin therapy. DESIGN: Retrospective analysis of daily quantitative and radiographic data on the cohort in a regional teaching hospital. RESULTS AND CONCLUSION: There was significant improvement in radiographic scores, when compared with day 1, on days 5, 6 and 7 (P < 0.05) after commencement of pentaglobin treatment. Similarly, there was significant improvement in oxygen requirement, when compared with day 1, on days 6 and 7 (P < 0.05) after commencement of pentaglobin treatment. There were no reported adverse events attributable to pentaglobin administration. Ten patients made an uneventful recovery after treatment. One elderly man died from cardio-respiratory arrest despite clinical and radiological improvement, and another patient is making good progress. Pentaglobin is safe and probably effective in the treatment of steroid-resistant SARS. A double-blind placebo-controlled study should therefore be considered.en_HK
dc.languageengen_HK
dc.publisherInternational Union against Tuberculosis and Lung Disease. The Journal's web site is located at http://www.theunion.org/about-the-journal/about-the-journal.htmlen_HK
dc.relation.ispartofInternational Journal of Tuberculosis and Lung Diseaseen_HK
dc.subjectCorticosteroiden_HK
dc.subjectImmunoglobulinen_HK
dc.subjectPentaglobinen_HK
dc.subjectSevere acute respiratory syndromeen_HK
dc.subjectTreatmenten_HK
dc.subject.meshAdrenal Cortex Hormones - therapeutic useen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshDrug Resistanceen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunoglobulin A - administration & dosage - therapeutic useen_HK
dc.subject.meshImmunoglobulin M - administration & dosage - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshRetrospective Studiesen_HK
dc.subject.meshRibavirin - therapeutic useen_HK
dc.subject.meshSevere Acute Respiratory Syndrome - radiography - therapyen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titlePentaglobin in steroid-resistant severe acute respiratory syndromeen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1027-3719&volume=8&issue=10&spage=1173&epage=1179&date=2004&atitle=Pentaglobin+in+steroid-resistant+severe+acute+respiratory+syndromeen_HK
dc.identifier.emailHo, JC:jhocm@hku.hken_HK
dc.identifier.emailKhong, PL:plkhong@hkucc.hku.hken_HK
dc.identifier.emailHo, PL:plho@hkucc.hku.hken_HK
dc.identifier.authorityHo, JC=rp00258en_HK
dc.identifier.authorityKhong, PL=rp00467en_HK
dc.identifier.authorityHo, PL=rp00406en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid15527148-
dc.identifier.scopuseid_2-s2.0-5644259643en_HK
dc.identifier.hkuros99153en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-5644259643&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume8en_HK
dc.identifier.issue10en_HK
dc.identifier.spage1173en_HK
dc.identifier.epage1179en_HK
dc.identifier.isiWOS:000224492500003-
dc.publisher.placeFranceen_HK
dc.identifier.scopusauthoridHo, JC=7402649981en_HK
dc.identifier.scopusauthoridWu, AY=7402998620en_HK
dc.identifier.scopusauthoridLam, B=9246012800en_HK
dc.identifier.scopusauthoridOoi, GC=7006176119en_HK
dc.identifier.scopusauthoridKhong, PL=7006693233en_HK
dc.identifier.scopusauthoridHo, PL=7402211363en_HK
dc.identifier.scopusauthoridChanYeung, M=54790582200en_HK
dc.identifier.scopusauthoridZhong, NS=7102137996en_HK
dc.identifier.scopusauthoridKo, C=8728540600en_HK
dc.identifier.scopusauthoridLam, WK=7203021937en_HK
dc.identifier.scopusauthoridTsang, KW=7201555024en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats